These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36718719)

  • 1. Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy.
    Hibma JE; Jayachandran P; Neelakantan S; Harnisch LO
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):375-386. PubMed ID: 36718719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy.
    Zamani G; Hosseinpour S; Ashrafi MR; Mohammadi M; Badv RS; Tavasoli AR; Akbari MG; Bereshneh AH; Malamiri RA; Heidari M
    BMC Neurol; 2022 May; 22(1):162. PubMed ID: 35501714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    Muntoni F; Domingos J; Manzur AY; Mayhew A; Guglieri M; ; Sajeev G; Signorovitch J; Ward SJ
    PLoS One; 2019; 14(9):e0221097. PubMed ID: 31479456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population longitudinal analysis of Gait Profile Score and North Star Ambulatory Assessment in children with Duchenne muscular dystrophy.
    Deng J; Liu F; Feng Z; Liu Z
    CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):891-903. PubMed ID: 38539027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.
    Bello L; Morgenroth LP; Gordish-Dressman H; Hoffman EP; McDonald CM; Cirak S;
    Neurology; 2016 Jul; 87(4):401-9. PubMed ID: 27343068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.
    Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN;
    J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial.
    Muntoni F; Guglieri M; Mah JK; Wagner KR; Brandsema JF; Butterfield RJ; McDonald CM; Mayhew AG; Palmer JP; Marraffino S; Charnas L; Mercuri E
    PLoS One; 2022; 17(8):e0272858. PubMed ID: 35998119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
    Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy.
    Zambon AA; Ayyar Gupta V; Ridout D; Manzur AY; Baranello G; Trucco F; Muntoni F;
    Dev Med Child Neurol; 2022 Aug; 64(8):979-988. PubMed ID: 35385138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the relationship between North Star Ambulatory Assessment and Health Utilities Index scores in Duchenne muscular dystrophy.
    Audhya I; Rogula B; Szabo SM; Feeny D; Bolatova T; Gooch K
    Health Qual Life Outcomes; 2023 Jul; 21(1):76. PubMed ID: 37468890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy.
    Ayyar Gupta V; Pitchforth JM; Domingos J; Ridout D; Iodice M; Rye C; Chesshyre M; Wolfe A; Selby V; Mayhew A; Mazzone ES; Ricotti V; Hogrel JY; Niks EH; de Groot I; Servais L; Straub V; Mercuri E; Manzur AY; Muntoni F;
    PLoS One; 2023; 18(4):e0283669. PubMed ID: 37099511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial.
    Mendell JR; Sahenk Z; Lehman KJ; Lowes LP; Reash NF; Iammarino MA; Alfano LN; Lewis S; Church K; Shell R; Potter RA; Griffin DA; Hogan M; Wang S; Mason S; Darton E; Rodino-Klapac LR
    Muscle Nerve; 2024 Jan; 69(1):93-98. PubMed ID: 37577753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.
    Muntoni F; Byrne BJ; McMillan HJ; Ryan MM; Wong BL; Dukart J; Bansal A; Cosson V; Dreghici R; Guridi M; Rabbia M; Staunton H; Tirucherai GS; Yen K; Yuan X; Wagner KR;
    Neurol Ther; 2024 Feb; 13(1):183-219. PubMed ID: 38190001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab.
    Sherlock SP; Palmer J; Wagner KR; Abdel-Hamid HZ; Bertini E; Tian C; Mah JK; Kostera-Pruszczyk A; Muntoni F; Guglieri M; Brandsema JF; Mercuri E; Butterfield RJ; McDonald CM; Charnas L; Marraffino S
    J Neurol; 2022 Aug; 269(8):4421-4435. PubMed ID: 35396602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
    Lennie JL; Mondick JT; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal natural history in young boys with Duchenne muscular dystrophy.
    Coratti G; Brogna C; Norcia G; Ricotti V; Abbott L; D'Amico A; Berardinelli A; Vita GL; Lucibello S; Messina S; Sansone V; Albamonte E; Colia G; Salmin F; Gardani A; Manzur A; Main M; Baranello G; Arnoldi MT; Parsons J; Carry T; Connolly AM; Bertini E; Muntoni F; Pane M; Mercuri E
    Neuromuscul Disord; 2019 Nov; 29(11):857-862. PubMed ID: 31629611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.